Primary Aldosteronism Market research report, Type (type I, type II), Indication (heart attack, kidney failure, stroke), by Diagnosis (blood test, imaging), Treatment (surgery, aldosterone antagonists), End User (hospitals) - forecast till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Primary Aldosteronism Market, by Type

6.1 Introduction

6.2 Type I

Market Estimates & Forecast, 2020 – 2027

6.3 Type II

Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Primary Aldosteronism Market, by Indications

7.1 Introduction

7.2 Heart Attack

Market Estimates & Forecast, 2020 – 2027

7.3 Kidney Failure

Market Estimates & Forecast, 2020 – 2027

7.4 Stroke

Market Estimates & Forecast, 2020 – 2027

7.5 Others

Chapter 8. Global Primary Aldosteronism Market, by Diagnosis

8.1 Introduction

8.2 Diagnosis

Market Estimates & Forecast, 2020 – 2027

8.2.1 Blood Test

8.2.1.1 Aldosterone Profiling

8.2.1.2 Renin Profiling

8.2.1.3 Others

8.2.2 Imaging

8.2.2.1 Computed Tomography (CT)

8.2.2.2 Positron Emission Tomography (PET)

8.2.2.3 Others

Chapter 9 Global Primary Aldosteronism Market, by End User

9.1 Introduction

9.2 Surgery

Market Estimates & Forecast, 2020 – 2027

9.3 Aldosterone Antagonists

Market Estimates & Forecast, 2020 – 2027

9.3.1 Spironolactone

9.3.2 Eplerenone

9.3.3 Others

Chapter 10 Global Primary Aldosteronism Market, by End User

10.1 Introduction

10.2 End User

Market Estimates & Forecast, 2020 – 2027

10.2.1 Hospitals & Clinics

10.2.2 Research Organization

10.2.3 Academic Institutes

10.2.4 Others

Chapter 11. Global Primary Aldosteronism Market, by Region

11.1 Introduction

11.2 America

11.2.1 North America

11.2.1.1 U.S.

11.2.1.1 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Oman

11.5.4 Kuwait

11.5.5 Qatar

11.5.6 Rest of the Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 Pfizer Inc.

13.1.1 Company Overview

13.1.2 Product Overview

13.1.3 Financials

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Sun Pharmaceutical Industries Ltd.

13.2.1 Company Overview

13.2.2 Product Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Bristol Laboratories Ltd

13.3.1 Company Overview

13.3.2 Product Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 CMP Pharma

13.4.1 Company Overview

13.4.2 Product/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Koninklijke Philips N.V.

13.5.1 Company Overview

13.5.2 Product Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 GE Healthcare

13.6.1 Company Overview

13.6.2 Product Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Siemens AG

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Shimadzu Corporation

13.8.1 Overview

13.8.2 Product Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Canon Inc.

13.9.1 Overview

13.9.2 Product Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of Pharmaceutical industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Primary Aldosteronism Industry Synopsis, 2020 – 2027

Table 2 Global Primary Aldosteronism Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Primary Aldosteronism Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 6 Global Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 7 Global Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 8 Global Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 9 North America Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 10 North America Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 11 North America Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 12 North America Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 13 North America Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 14 US Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 15 US Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 16 US Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 17 US Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 18 US Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 19 Canada Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 20 Canada Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 21 Canada Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 Canada Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 23 Canada Primary Aldosteronism Market by End User s, 2020 – 2027, (USD Million)

Table 24 South America Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 25 South America Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 26 South America Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 27 South America Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 28 South America Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 29 Europe Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 30 Europe Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 31 Europe Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 32 Europe Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 33 Europe Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 34 Western Primary Aldosteronism Europe Market by Type, 2020 – 2027, (USD Million)

Table 35 Western Europe Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 36 Western Europe Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 37 Western Europe Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 38 Western Europe Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 39 Eastern Europe Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 40 Eastern Europe Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 41 Eastern Europe Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 Eastern Europe Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 43 Eastern Europe Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 44 Asia Pacific Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 45 Asia Pacific Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 46 Asia Pacific Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 47 Asia Pacific Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 48 Asia Pacific Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 49 Middle East & Africa Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 50 Middle East & Africa Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 51 Middle East & Africa Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 52 Middle East & Africa Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 53 Middle East & Africa Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Primary Aldosteronism Market

Figure 3 Segmentation Market Dynamics for Global Primary Aldosteronism Market

Figure 4 Global Primary Aldosteronism Market Share, by Type 2020

Figure 5 Global Primary Aldosteronism Market Share, by Indications 2020

Figure 6 Global Primary Aldosteronism Market Share, by Diagnosis 2020

Figure 7 Global Primary Aldosteronism Market Share, by Treatment 2020

Figure 8 Global Primary Aldosteronism Market Share, by End User, 2020

Figure 9 Global Primary Aldosteronism Market Share, by Region, 2020

Figure 10 North America Primary Aldosteronism Market Share, by Country, 2020

Figure 11 Europe Primary Aldosteronism Market Share, by Country, 2020

Figure 12 Asia Pacific Primary Aldosteronism Market Share, by Country, 2020

Figure 13 Middle East & Africa Primary Aldosteronism Market Share, by Country, 2020

Figure 14 Global Primary Aldosteronism Market: Company Share Analysis, 2020 (%)

Figure 15 Pfizer Inc.: Key Financials

Figure 16 Pfizer Inc.: Segmental Revenue

Figure 17 Pfizer Inc.: Geographical Revenue

Figure 18 Sun Pharmaceutical Industries Ltd.: Key Financials

Figure 19 Sun Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 20 Sun Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 21 Bristol Laboratories Ltd: Key Financials

Figure 22 Bristol Laboratories Ltd: Segmental Revenue

Figure 23 Bristol Laboratories Ltd: Geographical Revenue

Figure 24 CMP Pharma.: Key Financials

Figure 25 CMP Pharma.: Segmental Revenue

Figure 26 CMP Pharma.: Geographical Revenue

Figure 27 Koninklijke Philips N.V.: Key Financials

Figure 28 Koninklijke Philips N.V.: Segmental Revenue

Figure 29 Koninklijke Philips N.V.: Geographical Revenue

Figure 30 GE Healthcare: Key Financials

Figure 31 GE Healthcare: Segmental Revenue

Figure 32 GE Healthcare: Geographical Revenue

Figure 33 Siemens AG: Key Financials

Figure 34 Siemens AG: Segmental Revenue

Figure 35 Siemens AG: Geographical Revenue

Figure 36 Shimadzu Corporation: Key Financials

Figure 37 Shimadzu Corporation: Segmental Revenue

Figure 38 Shimadzu Corporation: Geographical Revenue

Figure 39 Canon Inc.: Key Financials

Figure 40 Canon Inc.: Segmental Revenue

Figure 41 Canon Inc.: Geographical Revenue